Loading…
enGene Therapeutics Inc. is projected to rise to $2.78 by 2027, a +61% move from its current price of $1.72. ENGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.61 | $1.72 | $1.84 | +0.05% |
| May 30 | $1.57 | $1.72 | $1.89 | +0.11% |
| May 31 | $1.54 | $1.72 | $1.93 | +0.16% |
| Jun 1 | $1.51 | $1.72 | $1.96 | +0.22% |
| Jun 2 | $1.49 | $1.72 | $1.99 | +0.27% |
| Jun 3 | $1.47 | $1.73 | $2.02 | +0.33% |
| Jun 4 | $1.45 | $1.73 | $2.05 | +0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.45 | $1.73 | $2.05 | +0.38% |
| Week 2 | $1.36 | $1.73 | $2.21 | +0.77% |
| Week 3 | $1.29 | $1.74 | $2.34 | +1.15% |
| Week 4 | $1.24 | $1.75 | $2.46 | +1.54% |
| Week 5 | $1.19 | $1.75 | $2.58 | +1.93% |
| Week 6 | $1.15 | $1.76 | $2.68 | +2.32% |
| Week 7 | $1.12 | $1.77 | $2.79 | +2.71% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
enGene Therapeutics Inc. is a clinical-stage biotechnology company based in Montreal, Canada. Through its subsidiary enGene, Inc., it develops genetic medicines to help patients suffering from bladder cancer.
Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc.
and changed its name to enGene Therapeutics Inc. in April 2026.
ENGN trades at $1.64 with a market cap of $109.86M and a rank of 4188. The current price is $1.64, and the market position is reflected by the rank and market cap figures provided. The forecast suggests a multi-year bullish price trajectory beyond 2026, with 2027 avg $2.68, 2030 avg $3.07, and 2050 avg $9.09, alongside progressively higher max prices and ROIs (e.g., 87.5 in 2030 and 454.1 by 2050).
In 2026 the forecast shows min $1.44, avg $1.64, max $2.55 with ROI 0 and NEUTRAL sentiment, anchoring the start of a longer-upward path.
A major floor 16.3% below — a decisive break under it would weaken the trend.
The nearest floor, 16.3% below — buyers have tended to step in here.
The nearest ceiling, 414.5% above — a clean break opens room to run.
A major ceiling 607.6% above — clearing it would confirm fresh momentum.
Key ENGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ENGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.69 | Buy | $1.72 | Buy |
| MA 10 | $1.66 | Buy | $2.04 | Sell |
| MA 20 | $3.43 | Sell | $3.14 | Sell |
| MA 50 | $5.80 | Sell | $5.20 | Sell |
| MA 100 | $7.56 | Sell | $6.42 | Sell |
| MA 200 | $7.29 | Sell | $6.81 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 27.74 | Buy |
| Stoch RSI (14) | 96.43 | Sell |
| CCI (20) | -45.17 | Neutral |
| Williams %R (14) | -24.32 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 14.67 | Buy |
| Bollinger %B (20,2) | 0.35 | Neutral |
| Stochastic %K (14) | 75.68 | Neutral |
| TRIX (15) | -3.64 | Sell |
| Awesome (5,34) | -3.54 | Sell |
| Ultimate (7,14,28) | 34.41 | Neutral |
| Momentum (10) | 0.28 | Buy |
| Aroon Osc (25) | -16.00 | Sell |
| Hull MA (9) | 1.73 | Sell |
| ADX (14) | 38.38 | Sell |
| ATR (14) | 0.36 | Info |
The 30-day technical picture is NEUTRAL. RSI14 is 30, with the stock trading below its near-term averages. The SMA50 is $6.01 and the SMA200 is $7.31, indicating the price is currently below key long-term averages. The 30-day range spans from $1.05 to $2.56, with a support level at $1.44 and a resistance at $8.85.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.44 | $1.72 | $2.63 | 0% | Neutral | |
| $2.00 | $2.78 | $4.18 | +61% | Bullish | |
| $2.06 | $3.03 | $4.85 | +76% | Bullish | |
| $1.82 | $2.83 | $4.74 | +65% | Bullish | |
| $1.95 | $3.18 | $5.54 | +85% | Bullish | |
| $1.54 | $2.62 | $4.73 | +53% | Bullish | |
| $1.42 | $2.51 | $4.67 | +46% | Bullish | |
| $2.11 | $3.90 | $7.45 | +127% | Bullish | |
| $2.28 | $4.37 | $8.56 | +154% | Bullish | |
| $2.25 | $4.49 | $8.99 | +161% | Bullish | |
| $2.54 | $5.64 | $12.40 | +228% | Bullish | |
| $4.10 | $9.12 | $20.97 | +430% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.44 | $1.72 | $2.04 | +0.00% |
| June 2026 | $1.51 | $1.81 | $2.25 | +5.38% |
| July 2026 | $1.48 | $1.81 | $2.30 | -0.26% |
| August 2026 | $1.39 | $1.72 | $2.23 | -5.09% |
| September 2026 | $1.46 | $1.83 | $2.41 | +6.41% |
| October 2026 | $1.58 | $2.00 | $2.68 | +9.54% |
| November 2026 | $1.54 | $1.96 | $2.66 | -1.98% |
| December 2026 | $1.49 | $1.92 | $2.63 | -2.04% |
Click any year to see its month-by-month ENGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ENGN price prediction for 2026 points to an average of $1.72 (low $1.44, high $2.63) — a potential gain of 0% on today's $1.72. A consolidation phase looks the most probable path here.
In 2027, ENGN is projected to trade between $2.00 and $4.18, averaging $2.78 — a potential gain of +61% from today's $1.72. That is up +61% on the projected 2026 average. Momentum favours further upside here.
enGene Therapeutics Inc.'s 2028 outlook centres on $3.03, within a $2.06 to $4.85 range. That is up +9% on the projected 2027 average. That marks a +76% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, ENGN could reach as high as $4.74, with a base case around $2.83 and support toward $1.82 — roughly +65% from $1.72. Momentum favours further upside here.
Expect ENGN to range from $1.95 to $5.54 through 2030. The $3.18 average target implies a +85% move from current prices. That is up +12% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The ENGN price prediction for 2031 points to an average of $2.62 (low $1.54, high $4.73) — a potential gain of +53% on today's $1.72. Momentum favours further upside here.
In 2032, ENGN is projected to trade between $1.42 and $4.67, averaging $2.51 — a potential gain of +46% from today's $1.72. That is -4% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
enGene Therapeutics Inc.'s 2033 outlook centres on $3.90, within a $2.11 to $7.45 range. That is up +55% on the projected 2032 average. That marks a +127% change versus current levels. Momentum favours further upside here.
By 2034, ENGN could reach as high as $8.56, with a base case around $4.37 and support toward $2.28 — roughly +154% from $1.72. Buyers look set to stay in control over this stretch.
Expect ENGN to range from $2.25 to $8.99 through 2035. The $4.49 average target implies a +161% move from current prices. That is up +3% on the projected 2034 average. Momentum favours further upside here.
The ENGN price prediction for 2040 points to an average of $5.64 (low $2.54, high $12.40) — a potential gain of +228% on today's $1.72. Buyers look set to stay in control over this stretch.
In 2050, ENGN is projected to trade between $4.10 and $20.97, averaging $9.12 — a potential gain of +430% from today's $1.72. That is up +62% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ENGN today (≈ 581.395349 ENGN) could be worth
$5,299.62
+$4,299.62 (+430%) by 2050 · US Dollar
Based on the average projected ENGN price of $9.12 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ENGNwould be worth at today's price.
$1,000 invested in ENGN on May 27, 2025 (≈ 250 ENGN) would be worth
$430
-$570 (-57.0%) today · 0.43× · US Dollar
Based on a ENGN entry price of $4 vs. today's $1.72.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.61 | $1,068.32 | +6.8% |
| 1 month ago | $7.2 | $238.89 | -76.1% |
| 3 months ago | $10.03 | $171.49 | -82.9% |
| 6 months ago | $8.07 | $213.14 | -78.7% |
| 1 year ago | $4 | $430 | -57.0% |
| All time (4.3y) ago | $9.86 | $174.44 | -82.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ENGN forecast.
Our base-case forecast reaches $3.40 around 2033.
Implied market cap at $3.40: $227.76M
Looking across the multi-year forecast, the average price rises from $2.68 in 2027 to $2.91 in 2028 and $2.74 in 2029, then to $3.07 in 2030 with an ROI of 87.5. The forecast continues higher into the early 2030s, with 2033 avg $3.89, 2034 avg $4.26 and 2035 avg $4.40, and max values up to $7.43, $8.34 and $8.81, respectively, supported by bullish sentiment. By 2033–2035, the upside accelerates further with ROIs of 137.2, 159.5 and 168.1.
In 2040 the min is $2.51, avg $5.58, max $12.27 with ROI 240 and a bullish outlook, and by 2050 the min reaches $4.09, avg $9.09, max $20.90 with ROI 454.1 and continued bullish sentiment. Drivers include the progression of its NMIBC-related genetic medicines and the ongoing LEGEND Phase 2 pipeline, though these forecasts are estimates and not guarantees of future results.
Tap a question to reveal the answer.
2030 min $1.89, avg $3.07, max $5.36; ROI 87.5; sentiment BULLISH.
Forecasts show bullish sentiment in 2027 (avg $2.68) through 2050 (avg $9.09) with ROI reaching 454.1 by 2050; however, these are estimates and not guarantees.
Yes. The forecast max for 2030 is $5.36; later years show higher max values, including 2033 $7.43 and 2040 $12.27.
2027 min $1.93, avg $2.68, max $4.04; ROI 63.7; sentiment BULLISH.
Current price $1.64; 30-day range low $1.05, high $2.56.
enGene Therapeutics Inc. Community Discussion
0Share your enGene Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.